keyboard_arrow_up

Hypertrophic Scars Treatment Pipeline H1 2015 Review Research Report

RnRMarketResearch.com adds “Hypertrophic Scars – Pipeline Review, H1 2015” to its store.

The report “Hypertrophic Scars – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Hypertrophic Scars, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertrophic Scars and special features on late-stage and discontinued projects.

Complete report is available at http://www.rnrmarketresearch.com/hypertrophic-scars-pipeline-review-h1-2015-market-report.html .

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies discussed in this Hypertrophic Scars – Pipeline Review, H1 2015 report include HanAll Biopharma Co., Ltd., Pfizer Inc., RXi Pharmaceuticals Corporation, Sirnaomics, Inc., Symic Biomedical, Inc., Vida Therapeutics Inc.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are HL-156FIB, koebnerisin, PF-06473871, psoriasin, Recombinant Protein to Inhibit Granzyme B for Cardiovascular and Dermatology Diseases, RXI-109, Small Molecules for Wounds and Scars, STP-705, V-2248. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=382508 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report includes:

·         Mar 23, 2015: RXi Pharmaceuticals Reports Positive Advancements in its Dermatology Programs at the Occasion of the 73rd Annual Meeting of the American Academy of Dermatology

·         Mar 11, 2015: RXi Pharmaceuticals to Present at the 73rd Annual Meeting of the American Academy of Dermatology

·         Jan 22, 2015: Sirnaomics Files to Begin Trial of Scar-healing Drug in China as it Seeks Funding in US

·         Jan 05, 2015: Sirnaomics and Partner Submit IND to CFDA

·         Oct 07, 2014: RXi Pharmaceuticals to Present New Data in its First Phase 2a Clinical Trial with RXI-109

·         Sep 18, 2014: RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference

·         Sep 11, 2014: RXi Pharmaceuticals Presented an Update on the Company's Dermatology and Ophthalmology Franchises

·         Sep 03, 2014: RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference

·         Jul 30, 2014: RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars

·         May 02, 2014: RXi Pharmaceuticals Announces Positive Results with RXI-109 in the Eyes of Cynomolgus Monkeys as Part of a Dose Range Finding Study

List of Tables
Number of Products under Development for Hypertrophic Scars, H1 2015 8
Number of Products under Development for Hypertrophic Scars - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Hypertrophic Scars - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 16
Hypertrophic Scars - Pipeline by Pfizer Inc., H1 2015 17
Hypertrophic Scars - Pipeline by RXi Pharmaceuticals Corporation, H1 2015 18
Hypertrophic Scars - Pipeline by Sirnaomics, Inc., H1 2015 19
Hypertrophic Scars - Pipeline by Symic Biomedical, Inc., H1 2015 20
Hypertrophic Scars - Pipeline by Vida Therapeutics Inc., H1 2015 21
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Stage and Target, H1 2015 24
Number of Products by Stage and Mechanism of Action, H1 2015 26
Number of Products by Stage and Route of Administration, H1 2015 28
Number of Products by Stage and Molecule Type, H1 2015 30
Hypertrophic Scars Therapeutics - Recent Pipeline Updates, H1 2015 43
Hypertrophic Scars - Dormant Projects, H1 2015 49
Hypertrophic Scars - Discontinued Products, H1 2015 50

List of Figures
Number of Products under Development for Hypertrophic Scars, H1 2015 8
Number of Products under Development for Hypertrophic Scars - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Top 10 Targets, H1 2015 23
Number of Products by Stage and Top 10 Targets, H1 2015 24
Number of Products by Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 26
Number of Products by Top 10 Routes of Administration, H1 2015 27
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 28
Number of Products by Top 10 Molecule Types, H1 2015 29
Number of Products by Stage and Top 10 Molecule Types, H1 2015 30

Explore more reports on Dermatology therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics .